

Reference number(s)
3348-A

Standard Medicare Part B Management

Beovu

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Beovu	brolucizumab-dbll

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications¹

- Neovascular (wet) age-related macular degeneration
- Diabetic macular edema

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

Coverage Criteria

Neovascular (Wet) Age-Related Macular Degeneration^{1,2}

Authorization of 12 months may be granted for treatment of neovascular (wet) age-related macular degeneration.

Diabetic Macular Edema¹

Authorization of 12 months may be granted for treatment of diabetic macular edema.

Reference number(s)
3348-A

Continuation of Therapy

All members (including new members) requesting authorization for continuation of therapy must be currently receiving therapy with the requested agent.

Authorization of 12 months may be granted when all of the following criteria are met:

- The member is currently receiving therapy with the requested medication.
- The requested medication is being used to treat an indication in the coverage criteria section.
- The member demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or vision field, or a reduction in the rate of vision decline or the risk of more severe vision loss).

Summary of Evidence

The contents of this policy were created after examining the following resources:

- The prescribing information for Beovu.
- The available compendium
 - National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium
 - Micromedex DrugDex
 - American Hospital Formulary Service- Drug Information (AHFS-DI)
 - Lexi-Drugs
 - Clinical Pharmacology

After reviewing the information in the above resources, the FDA-approved indications listed in the prescribing information for Beovu are covered.

Explanation of Rationale

Support for FDA-approved indications can be found in the manufacturer's prescribing information.

References

1. Beovu [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2023.
2. Dugel PU, Koh A, Ogura Y et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020; 127:72-84